Related Experiment Videos
Platelet hyperaggregability in ischemic cerebrovascular disease and effects of aspirin
Insights
In patients with chronic ischemic cerebrovascular disease (CVD), platelet aggregation increased in cerebral venous blood. Aspirin therapy suppressed this effect, suggesting its prophylactic benefit for CVD patients.
Area of Science:
- Neuroscience
- Hematology
- Pharmacology
Background:
- Ischemic cerebrovascular disease (CVD) involves impaired blood flow to the brain.
- Platelet aggregation plays a crucial role in thrombotic events, including those causing CVD.
- Understanding platelet behavior in CVD is vital for developing effective treatments.
Purpose of the Study:
- To investigate platelet aggregation differences in cerebral and peripheral blood of patients with chronic ischemic CVD.
- To evaluate the impact of aspirin on platelet aggregability in these patients.
Main Methods:
- Studied platelet aggregation in carotid arterial, internal jugular venous, and peripheral venous blood from 24 chronic ischemic CVD patients.
- Conducted aggregation tests using sodium arachidonate (A.A.) and adenosine diphosphate (ADP) at varying concentrations.
- Compared results between patients not taking aspirin and those taking ≥500 mg oral aspirin daily.
Main Results:
- In 17 patients not on aspirin, platelet aggregability was significantly higher in jugular venous blood compared to arterial and peripheral venous blood.
- This difference was more pronounced in patients with cerebral artery stenosis or occlusion.
- In 7 patients on aspirin, no aggregation differences were observed across the brain, and A.A.-induced aggregation and the second phase of ADP-induced aggregation were fully suppressed.
Conclusions:
- Platelet aggregation is enhanced within the cerebral circulation of patients with chronic ischemic CVD.
- Aspirin effectively suppresses this enhanced platelet aggregation, indicating its potential prophylactic value.
- Prophylactic aspirin administration may be beneficial for managing chronic ischemic cerebrovascular disease.
Abstract:
Platelet aggregation was studied in 24 patients in the chronic stage of ischemic cerebrovascular disease (CVD), with cerebral affluent and effluent blood, i.e., carotid arterial and internal jugular venous blood, and also with peripheral venous blood. Aggregation tests were performed at various final concentrations of sodium arachidonate (A.A.) and ADP. In 17 patients, not taking aspirin, platelet aggregability in jugular venous blood was significantly accentuated compared with that in arterial and peripheral venous blood. This tendency was more marked in the patients with cerebral artery stenosis and/or occlusion than in those with normal cerebral angiogram. In 7 patients taking 500 mg or more oral aspirin, aggregation differences across the brain were not observed and A.A. aggregation and the second phase of ADP aggregation were completely suppressed. These results suggest that a prophylactic administration of aspirin may be beneficial for patients in chronic stage of CVD.